Regeneron Pharmaceuticals has announced its acquisition of 23andMe for $256 million, occurring shortly after 23andMe filed for Chapter 11 bankruptcy. This acquisition aims to bolster 23andMe's mission of aiding consumers in understanding their genetics, despite past profitability challenges and privacy concerns, particularly following a data breach. The deal will encompass 23andMe's personal genome service and health research services, but will leave behind its telehealth subsidiary, Lemonaid Health. Regeneron's commitment includes adherence to privacy policies, ensuring data protection and customer consent remain priorities in the integration process.
Regeneron's acquisition is aimed at enhancing 23andMe's mission of helping individuals understand their DNA, while ensuring compliance with privacy protocols.
With Regeneron's backing, 23andMe will continue to operate under privacy guidelines and focus on its goal of personal health improvement.
Collection
[
|
...
]